MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Sialorrhea"

  • 2019 International Congress

    Parotitis as Adverse Event Following BoNT Injections for Sialorrhea

    K. Papesh, J. Nguyen (Las Vegas, NV, USA)

    Objective: Review potential adverse events of parotitis with botulinum toxin injections for sialorrhea. Background: Sialorrhea is a common non-motor symptom of Parkinson’s disease. Botulinum toxin…
  • 2019 International Congress

    Atropine as Alternate Therapy for Treatment of Sialorrhea in Parksinson’s Disease

    K. Papesh, J. Nguyen (Las Vegas, NV, USA)

    Objective: Evaluating effectiveness of sublingual Atropine 1% ophthalmic solution for treatment of sialorrhea in Parkinson’s disease. Background: Sialorrhea is common non-motor symptom of Parkinson’s disease.…
  • 2019 International Congress

    Correlation Between Drooling and Quality of Life in Parkinson’s Disease

    O. Criciotoiu, D. Stanca, R. Latea, L. Giurgiulescu, A. Mita, V. Gheorman, D. Gheonea (Craiova, Romania)

    Objective: The aim of this study was to evaluate the relationship between the quality of life and drooling in Parkinson’s disease patients. Background: Parkinson’s disease…
  • 2019 International Congress

    Incidence of drooling in Parkinson’s Disease and Impact on Quality of Life

    B. Gibbons, B. Mohamed, C. Thomas (Cardiff, United Kingdom)

    Objective: The project aimed to determine the frequency and severity of drooling in the Parkinson’s Disease (PD) population in Cardiff & the Vale Health-board through…
  • 2019 International Congress

    Glycopyrrolate as inhalation for treating sialorrhea in Parkinson’s Disease

    L. Velzen, J. Masselink, L. Dorresteijn, K. Movig (Enschede, Netherlands)

    Objective: To evaluate the safety, tolerability and effect of glycopyrrolate inhalations in PD patients with sialorrhea. Background: Sialorrhea is reported in up to 60 percent…
  • 2018 International Congress

    Effects of Botulinum Toxin treatment for sialorrhea in patients with cerebral palsy

    J. Francês Brito, M. Akkari, A. Pinheiro Alves, A. Barbosa de Sousa Junior, B. De Oliveira, O. Vieira Kishi, Jose Roberto Bentes Capeloni (Belem, Brazil)

    Objective: To evaluate the benefits of treatment of drooling with Botulinum Toxin Type A (AbobotulinumtoxinA) in patients with cerebral palsy. Background: Patients with cerebral palsy…
  • 2018 International Congress

    Efficacy of incobotulinumtoxinA in patients with sialorrhea, as assessed using the modified Radboud Oral Motor Inventory for Parkinson’s disease (mROMP): Results of the SIAXI study

    W. Jost, A. Friedman, O. Michel, C. Oehlwein, J. Slawek, A. Bogucki, S. Ochudlo, M. Banach, F. Pagan, B. Flatau-Baqué, J. Csikós, A. Blitzer (Wolfach, Germany)

    Objective: The pivotal double-blind, randomised Phase III SIAXI study (NCT02091739), assessed the efficacy and safety of incobotulinumtoxinA 75 or 100 U for sialorrhea. Co-primary endpoints…
  • 2018 International Congress

    Long-term efficacy and safety of incobotulinumtoxinA treatment for sialorrhea in Parkinson’s disease and other neurologic conditions

    F. Pagan, W. Jost, A. Friedman, O. Michel, C. Oehlwein, J. Slawek, A. Bogucki, S. Ochudlo, M. Banach, B. Flatau-Baqué, J. Csikós, A. Blitzer (Washington, DC, USA)

    Objective: SIAXI (NCT02091739), a pivotal double-blind, randomised, placebo-controlled study with a 48-week extension period (EP), assessed the efficacy and safety of incobotulinumtoxinA 75 U or…
  • 2018 International Congress

    Impact of injection guidance techniques on the efficacy and safety of incobotulinumtoxinA for sialorrhea

    F. Pagan, W. Jost, A. Friedman, O. Michel, C. Oehlwein, J. Slawek, A. Bogucki, S. Ochudlo, M. Banach, B. Flatau-Baqué, J. Csikós, A. Blitzer (Washington, DC, USA)

    Objective: SIAXI (NCT02091739), a pivotal double-blind, randomised, placebo-controlled study with an extension period (EP), assessed the efficacy and safety of incobotulinumtoxinA 75 or 100 U…
  • 2017 International Congress

    Saliva changes and the oral health in Parkinson´s disease

    J. Tiigimäe-Saar, T. Tamme, P. Taba (Tartu, Estonia)

    Objective: The aim of this study was to determine the risk of change in the oral microflora and oral health in PD patients. Background: Parkinson…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley